Fortress Biotech Inc Pref Series A (FBIOP) revenue breakdown
By segment, Journey is the largest at 98% of fiscal 2025 revenue, growing 19% a year over 8 years.
By product, Qbrexza is the largest at 41% of fiscal 2025 revenue, growing 10% a year over 4 years.
Revenue by segment
Fiscal years, as Fortress Biotech Inc Pref Series A reports them in its 10-K filings; fiscal 2025 total $63M.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $16M | $23M | $35M | $45M | $63M | $74M | $79M | $56M | $62M | 98% |
| Avenue | — | — | — | — | — | — | — | — | $1M | 2% |
| Fortress | — | — | — | — | — | — | $5M | $2M | — | — |
| Checkpoint Merger | — | — | — | — | — | — | $103,000 | $41,000 | — | — |
| Pharmaceutical and Biotechnology Product Development | $2M | $4M | $2M | $1M | $6M | $2M | — | — | — | — |
Revenue by product
Fiscal years, as Fortress Biotech Inc Pref Series A reports them in its 10-K filings; fiscal 2025 total $61M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Qbrexza | — | — | — | — | $17M | $27M | $25M | $25M | $25M | 41% |
| Emrosi | — | — | — | — | — | — | — | — | $15M | 24% |
| Accutane | — | — | — | — | $10M | $18M | $20M | $19M | $13M | 21% |
| Foam franchise products (Amzeeq & Zilxi) | — | — | — | — | — | — | — | $7M | $6M | 10% |
| Other / legacy product revenue | — | — | — | — | — | — | $6M | $4M | $3M | 4% |
| Targadox | $14M | $21M | $28M | $31M | $22M | $8M | — | — | — | — |
| Amzeeq | — | — | — | — | — | $7M | $6M | — | — | — |
| Ximino | — | — | — | $10M | $8M | $5M | — | — | — | — |
| Exelderm | — | — | — | $4M | $5M | $3M | — | — | — | — |
| Zilxi | — | — | — | — | — | $2M | $2M | — | — | — |
| Other Branded Revenue | $2M | $2M | $7M | -$148,000 | $37,000 | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FBIOP.
Open FBIOP in InvestinglyQuestions
Where does Fortress Biotech Inc Pref Series A make its money?
In fiscal 2025, by segment: Journey $62M, Avenue $1M.
From Fortress Biotech Inc Pref Series A's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.